NCT03654768 2025-12-18
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT04258943 2025-09-18
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
Children's Oncology Group
Phase 1/2 Active not recruiting
NCT07091019 2025-07-29
ASC4REAL-2
Novartis
Not yet recruiting
NCT06423911 2025-06-03
POLARIS-2
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT04793399 2024-03-19
Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica
Phase 1/2 Terminated
NCT03885830 2023-01-11
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
UNC Lineberger Comprehensive Cancer Center
Completed
NCT04006847 2022-07-01
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT02782403 2020-11-19
Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02906696 2020-05-11
Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure
M.D. Anderson Cancer Center
Phase 2 Terminated